SciSparc Collaborates with Clearmind to File Patent for Depression Treatment
The company states: "SciSparc has reported that pursuant to NeuroThera's ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder. This innovative treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide sourced by NeuroThera. The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled "Depressive Disorder (Depression)", published in August 2025 Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors and other conventional options."
